November 5, 2026

COVID: Transmission

Susceptibility of Human Neural Stem Cells to SARS-CoV-2: Entry Mechanisms and Glycocalyx Influence
These investigators hypothesized that neural stem cells (NSCs) derived from human ectoderm are susceptible to SARS-CoV-2. Using pseudotyped viral particles representing both wild-type and Omicron spike variants, they confirmed efficient transduction in NSCs, with Omicron variants preferentially utilizing endocytosis-mediated entry. Inhibition of endocytosis with filipin and OcTMAB significantly reduced viral entry across all spike variants. Low glycosylation levels on NSCs facilitated viral entry, and enzymatic removal of glycosylation increased their susceptibility. Ectodermal infection by SARS-CoV-2 raises serious concern for potential teratogenic effects on the nervous system, possibly causing latent or subclinical anomalies not immediately evident at birth.  Future clinical studies and long-term surveillance of infants and children exposed in utero are necessary to investigate and identify potential neurodevelopmental deficits.

Comparing the Risk of Maternal Complications and Adverse Infant Outcomes Among Pregnancies With and Without COVID-19 in the Sentinel System
This retrospective study assessed the timing and severity of COVID-19 infection during pregnancy on adverse maternal and infant outcomes among live-birth pregnancies in the U.S. from 2020 to 2023. Among nearly 70,000 pregnancies with COVID-19, there was a modestly increased risk of cesarean section and preterm birth among pregnancies with severe COVID-19 infection compared to matched pregnancies without COVID-19.  Authors found no increased risk of adverse infant outcomes among 23,000 linked mother-infant pairs with COVID-19 although there was an elevated risk of low birth weight among mother-infant pairs with severe COVID-19 in the third trimester.

COVID: The Late Phase/PASC/Long COVID

Post-Vaccination Chemosensory Dysfunction: Changes Following SARS-CoV-2 Vaccination in a Global Study
Authors examined individuals with COVID-19 chemosensory impairment (smell and taste issues after COVID-19) and looked at the impact of getting them a vaccine dose. Pfizer-BioNTech accounted for 46.2% of vaccine doses, followed by Sputnik V (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%). More than 90% of participants reported no change in general smell or taste following vaccination, regardless of pre-existing chemosensory impairment. Among participants with qualitative chemosensory distortions, improvement was reported by 11%–18% for parosmia, 20%–29% for phantosmia, and 12%–21% for distorted taste, depending on vaccine dose, whereas worsening was reported by 3% or fewer.

Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial
These are the results of a decentralized, randomized, parallel group, double-blind, placebo-controlled clinical trial. Participants were randomized 1:1 to receive oral LDN (starting at 1.0 mg daily, increasing to 4.5 mg as tolerated) or placebo for 16 weeks. The primary outcome was fatigue severity, measured using the Fatigue Severity Scale (FSS). Secondary outcomes were pain (pain visual analogue scale [VAS]), ME/CFS total symptom score (PQSymp-12), daily step count, and health-related quality of life (EQ-5D-5L utility). Of the 160 enrolled participants, baseline characteristics were similar between the LDN (n=81) and placebo (n=79) groups. At 16 weeks, there was no difference in the mean FSS score between groups, no differences in pain, or any of the endpoints. Adverse events grade 3 or higher were reported almost twice as often in the LDN as in the placebo groups. Compared to  placebo, LDN at doses up to 4.5 mg/day for 16 weeks did not show any benefit.

Metformin at the Time of COVID-19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Authors conducted a new user analysis of metformin prescribed within six days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS-CoV-2 infection was associated with a 53% lower risk of LC over six months than comparator medications.

Situation Dashboards

World_Health_Organization_logo_logotype

World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
university-logo-small-horizontal-blue-no-clear-space-51c7fb4524

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
1point3acres

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
image

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information

World_Health_Organization_logo_logotype

World Health Organization (WHO)

U.S. Centers for Disease Control and Prevention

Centers for Disease Control, US

International Society for Infectious Diseases

International Society for Infectious Diseases

twiv-logo

This Week in Virology (TWIV)

Row triangle Shape Decorative svg added to bottom

Learn more about parasitic diseases and receive updates about Parasites Without Borders' initiatives and developments by subscribing to our newsletter.

Parasites Without Borders

Un recurso educativo integral sobre todos los aspectos de las enfermedades parasitarias y su impacto en la humanidad en todo el mundo.

Donate to Parasites Without Borders Today!

Ayude a llevar la información médica y biológica más reciente sobre enfermedades causadas por parásitos eucariotas a todos los médicos y estudiantes de medicina en los Estados Unidos.

Scroll al inicio